Bellicum, Bambino Gesu Children's Hospital deal

Bellicum and the hospital partnered to jointly develop CAR T cell and T cell receptor (TCR) therapies discovered by the hospital and engineered with Bellicum’s CaspaCIDe molecular safety switch technology. Bellicum will provide up to $4.4 million in research funding and gain exclusive, worldwide rights to commercialize developed therapies while the hospital will retain research-only rights. ...